| Předmět: |
|
| Zdroj: |
Clinical Trials Week; 2/6/2024, p917-917, 1p |
| Abstrakt: |
Researchers from the University of Indonesia have conducted a study on the effectiveness of sacubitril/valsartan in preventing heart failure in patients who have undergone percutaneous coronary intervention (PCI) following ST-elevation myocardial infarction (STEMI). The study found that sacubitril/valsartan was more effective than angiotensin-converting enzyme (ACE) inhibitors in reducing the risk of heart failure at 6 months post-PCI. The research suggests that sacubitril/valsartan may be a viable treatment option for reducing the risk of heart failure in STEMI patients. Further information on the study can be found in the Journal of Internal Medicine Indonesia. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
